Download presentation
Presentation is loading. Please wait.
Published byEmily Simmons Modified over 7 years ago
1
Pathophysiology of asthma and chronic obstructive pulmonary disease
M. Tatár
3
OBSTRUCTIVE LUNG DISEASES
localized: laryngeal constriction, tracheal and bronchial carcinoma, foreign bodies generalized: asthma, COPD, bronchiectasis, cystic fibrosis OBSTRUCTIVE VENTILATORY DISORDER - spirometry Airflow limitation
5
End of quiet expiration
- 0.5 - 2.5 0.5 Inspiration
6
Inspiration - 2.5 + 2.0 Forced expiration 0.5 - 2.0 - 1.5 - 1.0 - 0.5
7
Forced expiration + 2.0 0.5 + 2.5 + 2.0 + 1.5 + 1.0 EPP
8
Bronchial asthma
9
ASTHMA - definition Heterogeneous, multifactorial disease with variable and mostly reversible respiratory pathway obstruction based on a chronic bronchial inflammatory reaction. Symptoms (wheezing, cough particularly at night and early morning, dyspnoea – chest tightness or shortness of breath) are variable and correlated with expiratory flow limitation. Bronchial hyperresponsiveness is often present
10
Volume Normal subject Asthmatic (after bronchodilator) Asthmatic (before bronchodilator) FEV1 Time (seconds)
11
Classification A. Allergic asthma atopy, genetic predisposition
IgE, mast cells and eosinophils response to allergens A. Nonallergic asthma no environmental causes can be identified negative skin test to common airborn allergens rather negative family history C. Occupational asthma sensibilisation of airways to inhalant chemicals
12
Development of asthma Risk factors Predisposing - atopy, gender
Causal - allergens, aspirin, chemicals Contributing - respiratory infections, diet, air pollution, smoking Factors that exacerbate asthma - triggers allergens, respiratory infections, exercise, emotions
13
Triggers – mechanisms of action
Respiratory infections epithelial damage airway inflammation Exercise hyperventilation (reflex airflow limitation) - cooling of mucosa - osmolarity changes of fluid lining epithelium Emotions (laughing, crying, anger, fear) hyperventilation hypocapnia (bronchioloconstriction)
14
Key factor - airway inflammation Mechanisms - direct and indirect
Bronchial hyperresponsiveness Instability of the airways = exaggerated bronchoconstrictor response to a wide variety of stimuli Key factor - airway inflammation Mechanisms - direct and indirect
15
Airway hyperresponsiveness
Direct antagonists (methacholine) Nerve Airway with limited airflow SO2, bradykinin Mediators Indirect agonists (exercise, hypotonic or hypertonic aerosols Mast cell
16
antihyperreactive factors prohyperreactive factors
2-adrenergic -adrenergic VIP/PHM cholinergic anticholinergic SP/NK neutral peptidases free radicals antioxidants peptidases (Neu) corticoids
17
Pathological changes in airways
normal asthma epithelium basement membrane smooth muscle mucus plug mucus glands
18
Mechanisms of asthma 1. Airway inflammation
- recruitments of inflammatory cells from circulation - endothelial adhesion molecules - activation of T lymphocytes (Th2 clone) - production of IgE, leukotriens, prostanoids - cytokines (CD4+ Th subtype) - mast cells, eosinophils
19
Neural control of airways - neurogenic inflammation
Antigen etc. Macrophage Mast cell T-lymphocyte Neutrophil Eosinophil Mucus plug Epithelial shedding Vasodilation Subepithelial fibrosis Sensory nerve Plasma leak Efferent nerve Oedema Airway constriction and smooth muscle hypertrophy/hyperplasia
20
Mechanisms of expiratory flow limitation
1. Acute bronchoconstriction 2. Swelling of the airway wall - vasodilation - infiltration (Eo, Neu) 3. Chronic mucus plug formation 4. Airway wall remodeling
21
Bronchoconstriction airflow resistance
muscle constriction 35 % Normal R = 1 R = 10 muscle constriction 35 % Asthma R = 2 R = 40
22
(for development of asthma)
Risk factors (for development of asthma) INFLAMMATION Airway hyperresponsiveness Airflow limitation Risk factors (for exacerbations) Symptoms
25
Chronic obstructive pulmonary disease (COPD)
26
Definition Disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to inhaled noxious particles or gases. Chronic expiratory flow limitation - maximum expiratory flows - slow forced emptying of the lungs Combination of two pathological processes - airways damage - emphysema
27
COPD Chronic bronchitis Emphysema defined in clinical terms
chronic cough with sputum production - (3 months a year, 2 successive years) - excluded cardiac or other pulmonary causes Emphysema defined anatomically permanent, destructive enlagrement of airspaces distal to the terminal bronchioles without obvious fibrosis
28
Chronic airflow limitation - mechanisms
Chronic inflammation causes: - structural changes and narrowing of the small airways (obstructive bronchiolitis) - destruction of the lung parenchyma leads to the loss of alveolar attachments to the small airways and decreasing lung elastic recoil - these changes diminish the ability of the airways to remain open during expiration
31
1 - antitrypsin deficiency Heavily polluted environments
Risk factors Cigarette smoking 1 - antitrypsin deficiency Solid fuel used for indoor heating or cooking without adequate ventilation Heavily polluted environments
32
Never smoked Smoked regularly Stopped at age 45 yrs Disability
100 Never smoked 75 Smoked regularly FEV1 % Stopped at age 45 yrs 50 Disability 25 Stopped at age 65 yrs Death 25 75 50 Age yrs
33
Cellular and biochemical mechanisms
Inflammation: alveolar macrophages, CD8+ T lymphocytes, neutrophils production of elastase, cathepsine G, collagenase oxidative stress in smokers and in COPD patients Neutrophil and macrophage enzymes and oxidants destroy components of extracellular matrix (collagen, elastin, fibronectine, proteoglycans) Loss of cellular components of lung parenchyma: - elastase can induce apoptosis - cells exposed to oxidants may undergo necrosis
34
Imbalance proteases antiproteases system oxidants antioxidants Destruction of lung parenchyma Small airways disorder
39
Pathology of peripheral airways
mucus plugging goblet cell hyper/metaplasia fibrosis smooth muscle hypertrophy
40
Maximal expiratory efforts
Peak exp. flow 12 Maximal expiratory efforts 6 V´ ( l.s-1 ) - 6 25 50 75 100 VC ( % exhaled)
41
COPD phenotypes symptoms obstruction severity risk of exacerbations
occurrence of comorbidities
42
Frequent comorbidities
Loss of weight Dysfunction of skeletal muscles Osteoporosis Progression of aterosclerosis and coronary artery disease
43
Systemic inflammation
44
Local and systemic inflammation
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.